Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: GlobeNewswire
Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness, communication and seizure severity 75% reduction in median seizure rate seen for patients in the long-term extension Registrational phase of the EMBOLD study for SCN2A and 8A initiated BOSTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today shared positive topline results for its Phase 2, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. “We are thrilled to see the combination of positive efficacy and tolerability of relutrigine for SCN2A and 8A, where there
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $111.00 price target on the stock.MarketBeat
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $150.00 price target on the stock.MarketBeat
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Praxis Precision Medicines to Present at Two February Investor ConferencesGlobeNewswire
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target raised by analysts at Truist Financial Co. from $150.00 to $175.00. They now have a "buy" rating on the stock.MarketBeat
PRAX
Earnings
- 11/6/24 - Miss
PRAX
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form 4
- 2/14/25 - Form 4
- PRAX's page on the SEC website